Literature DB >> 5062099

Inhibition of prolactin secretion and successful therapy of the Forbes-Albright syndrome with L-dopa.

R W Turkington.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5062099     DOI: 10.1210/jcem-34-2-306

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  7 in total

1.  The effect of levodopa on galactorrhea in the Forbes-Albright syndrome.

Authors:  M Edmonds; H Friesen
Journal:  Can Med Assoc J       Date:  1972-09-23       Impact factor: 8.262

2.  Effect of vitamin B6 on the serum concentration of pituitary hormones in normal humans and under pathologic conditions.

Authors:  M Bigazzi; S Ferraro; R Ronga; G Scarselli; V Bruni; A L Olivotti
Journal:  J Endocrinol Invest       Date:  1979 Apr-Jun       Impact factor: 4.256

3.  Use of blockers and stimulators of prolactin secretion in persistent lactorrhea-amenorrhea syndrome.

Authors:  N T Starkova; G A Mel'nichenko
Journal:  Neurosci Behav Physiol       Date:  1980 Nov-Dec

4.  Treatment of galactorrhea-amenorrhea syndrome with 2-Br-alpha-ergocryptin (CB 154). Clinical response and pattern of pituitary and steriod hormones before and during therapy.

Authors:  H J Künzig; W Geiger; K D Schulz; K H Lose
Journal:  Arch Gynakol       Date:  1975

5.  Galactorrhoea: successful treatment with reduction of plasma prolactin levels by brom-ergocryptine.

Authors:  G M Besser; L Parke; C R Edwards; I A Forsyth; A S McNeilly
Journal:  Br Med J       Date:  1972-09-16

6.  Effects of short-term and long-term hyperprolactinemia on the developmental pattern of androgen and LH levels in the immature male rat.

Authors:  D Maric; I Simonovic; R Kovacevic; L Krsmanovic; S Stojilkovic; R K Andjus
Journal:  J Endocrinol Invest       Date:  1982 Jul-Aug       Impact factor: 4.256

7.  Hypothalamic-pituitary function in diverse hyperprolactinemic states.

Authors:  R M Boyar; S Kapen; J W Finkelstein; M Perlow; J F Sassin; D K Fukushima; E D Weitzman; L Hellman
Journal:  J Clin Invest       Date:  1974-06       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.